share_log

Intelligent Bio Solutions | 424B3: Prospectus

SEC announcement ·  Mar 18 13:10
Summary by Moomoo AI
Intelligent Bio Solutions Inc. has filed a prospectus with the SEC under Rule 424(b)(3) for the resale of up to 636,367 shares of common stock by selling stockholders. These shares are issuable upon the exercise of Series G Warrants and Placement Agent Warrants issued on February 7, 2024. The company will not sell any shares or receive proceeds from the selling stockholders' sales. The selling stockholders may sell the shares at fixed or negotiated prices through various methods, including block trades, private transactions, or on the Nasdaq Capital Market where the company's stock is listed under the symbol 'INBS'. The last reported sale price of the company's common stock was $4.39 per share as of March 15, 2024. The prospectus also details the company...Show More
Intelligent Bio Solutions Inc. has filed a prospectus with the SEC under Rule 424(b)(3) for the resale of up to 636,367 shares of common stock by selling stockholders. These shares are issuable upon the exercise of Series G Warrants and Placement Agent Warrants issued on February 7, 2024. The company will not sell any shares or receive proceeds from the selling stockholders' sales. The selling stockholders may sell the shares at fixed or negotiated prices through various methods, including block trades, private transactions, or on the Nasdaq Capital Market where the company's stock is listed under the symbol 'INBS'. The last reported sale price of the company's common stock was $4.39 per share as of March 15, 2024. The prospectus also details the company's recent developments, including a reverse stock split in January 2024 to regain compliance with Nasdaq's minimum bid price requirement, and the appointment of a liquidator for the licensor of the company's SGT and COV2T products. Intelligent Bio Solutions Inc. is a medical technology company focused on developing non-invasive testing and screening solutions, with a product portfolio that includes the Intelligent Fingerprinting Drug Screening System and the Biosensor Platform for diagnostic testing.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more